Shen-Kang protects against tacrolimus-induced renal injury

作者：Zhang, Long Ye; Jin, Jian; Luo, Kang; Piao, Shang Guo; Zheng, Hai Lan; Jin, Ji Zhe; Lim, Sun Woo; Choi, Bum Soon; Yang, Chul Woo; Li, Can^*

来源：Korean Journal of Internal Medicine, 2019, 34(5): 1078-1090.

DOI：10.3904/kjim.2017.276

• Tacrolimus
• Shen-Kang
• Transforming growth factor beta1
• Apoptosis
• Oxidative stress

Background/Aims: Evidence suggests that Shen-Kang (SK), a traditional Chinese herbal medicine, protects against various types of renal injury. In this study, we evaluated whether SK treatment confers renoprotection in a rat model of chronic tacrolimus (TAC) nephropathy.
Methods: Rats were treated daily with TAC (1.5 mg/kg, subcutaneously) and SK (450 mg/kg, intravenously) for 4 weeks. The effects of SK on TAC-induced renal injury were assessed by measuring renal function, urine albumin excretion, histopathology, inflammatory cell infiltration, expression of profibrotic (transforming growth factor beta 1 [TGF-beta 1] and TGF-beta inducible gene-h3 [beta ig-h3]) and proinflammatory cytokines, oxidative stress, and apoptotic cell death.
Results: Administration of SK preserved glomerular integrity (fractional mesangial area and Wilms tumor 1-positive glomeruli), attenuated tubulointerstitial fibrosis, and reduced the number of ectodermal dysplasia 1-positive cells, and this was paralleled by improved urine albumin excretion and renal dysfunction. At the molecular level, SK treatment suppressed expression of TGF-beta 1/Smad2/3, beta ig-h3, and proinflammatory cytokines. Oxidative stress and apoptotic cell death were significantly decreased with SK treatment, and apoptosis-related genes were regulated toward cell survival (active caspase-3 and the B-cell lymphoma-2 / Bcl2-associated X [Bcl-2/Bax] ratio).
Conclusions: SK protects against TAC-induced renal injury.

• 出版日期2019-9
• 单位延边大学